To support its function, a subset of myeloid cells co-expressing ARG1 and TREM-2 were identified in several preclinical models of cancers and genetic ablation of TREM-2 in mice inhibited accumulation of intra-tumour myeloid cells, leading to a decrease in dysfunctional CD8+ T cells and reduced tumour growth [194]. The gene discussed is TREM2; the disease is cancer.